Columbia Partners L L C Investment Management lessened its stake in shares of TESARO, Inc. (NASDAQ:TSRO) by 22.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,096 shares of the biopharmaceutical company’s stock after selling 3,173 shares during the quarter. Columbia Partners L L C Investment Management’s holdings in TESARO were worth $1,432,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Exane Derivatives bought a new stake in TESARO during the 3rd quarter valued at $106,000. Botty Investors LLC acquired a new stake in shares of TESARO in the 2nd quarter worth $140,000. Nordea Investment Management AB acquired a new stake in shares of TESARO in the 2nd quarter worth $167,000. Oppenheimer Asset Management Inc. boosted its position in shares of TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,430 shares in the last quarter. Finally, Toronto Dominion Bank boosted its position in shares of TESARO by 244.6% in the 3rd quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares in the last quarter.
In related news, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $134.92, for a total value of $1,465,501.04. Following the completion of the transaction, the vice president now owns 6,258 shares of the company’s stock, valued at approximately $844,329.36. The disclosure for this sale can be found here. Insiders have sold a total of 35,692 shares of company stock valued at $4,628,976 in the last quarter. Company insiders own 40.50% of the company’s stock.
TSRO has been the subject of a number of recent analyst reports. Citigroup Inc. reissued a “buy” rating and issued a $216.00 price objective on shares of TESARO in a research report on Monday, September 11th. Robert W. Baird reissued a “neutral” rating and issued a $140.00 price objective (down previously from $155.00) on shares of TESARO in a research report on Thursday, August 10th. Jefferies Group LLC reissued a “hold” rating and issued a $124.00 price objective on shares of TESARO in a research report on Friday, November 3rd. Credit Suisse Group set a $190.00 price objective on TESARO and gave the stock a “buy” rating in a research report on Friday, August 18th. Finally, HC Wainwright reissued a “buy” rating on shares of TESARO in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. TESARO has a consensus rating of “Buy” and a consensus target price of $161.72.
TESARO, Inc. (NASDAQ TSRO) traded down $2.10 during midday trading on Friday, hitting $85.90. The company’s stock had a trading volume of 447,902 shares, compared to its average volume of 1,031,102. TESARO, Inc. has a twelve month low of $84.42 and a twelve month high of $192.94. The company has a quick ratio of 4.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.69. The business had revenue of $142.77 million during the quarter, compared to analyst estimates of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The company’s revenue was up 740.3% on a year-over-year basis. During the same quarter last year, the business posted ($1.72) EPS. analysts forecast that TESARO, Inc. will post -8.18 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/18/columbia-partners-l-l-c-investment-management-sells-3173-shares-of-tesaro-inc-tsro.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.